| Previous Close | 2.99 |
| Open | 2.95 |
| Day High | 2.96 |
| Day Low | 2.69 |
| 52-Week High | 33.68 |
| 52-Week Low | 2.7 |
| Volume | 1.05M |
| Average Volume | 803,350 |
| Market Cap | 150.07M |
| PE | -0.94 |
| EPS | -2.91 |
| Moving Average 50 Days | 5.33 |
| Moving Average 200 Days | 9.97 |
| Change | -0.25 |
Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting
GlobeNewswire Inc.
Mar 01, 2026 2:45 PM GMT
– Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p < 0.0001) in new analysis with adjustment for concomitant rescue therapy use – – Secondary endpoints also provided strong efficacy data in new analyses, including r
Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026
GlobeNewswire Inc.
Feb 26, 2026 12:00 PM GMT
– New analyses of efficacy endpoints from the Phase 2 VIBRANT trial of verekitug in CRSwNP to be presented during the late-breaking poster session – WALTHAM, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stag
Upstream Bio to Participate in Upcoming March Investor Conferences
GlobeNewswire Inc.
Feb 25, 2026 12:00 PM GMT
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherlan